SVCM
MNPR icon

Saturn V Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Saturn V Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.9M Buy
345,626
+19,925
+6% +$1.2M 3.43% 12
2025
Q4 		$21.3M Buy
325,701
+170,331
+110% +$13.9M 3.9% 12
2025
Q3 		$12.7M Buy
+155,370
New +$6.95M 2.78% 16

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Saturn V Capital Management's MNPR Position: Q1 2026 in Review

Saturn V Capital Management increased its Monopar Therapeutics (MNPR) stake by 6.1% in Q1 2026, buying an estimated $1.2M and bringing the position to 345,626 shares worth $18.9M. The position accounts for 3.43% of the portfolio, ranked #12.

Saturn V Capital Management first reported a position in MNPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $21.3M in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Saturn V Capital Management held 345,626 shares of Monopar Therapeutics worth $18.9M as of Q1 2026.
  • Saturn V Capital Management bought 19,925 Monopar Therapeutics shares in Q1 2026, an estimated $1.2M.
  • Monopar Therapeutics made up 3.43% of Saturn V Capital Management's portfolio in Q1 2026, its #12 holding.
  • Saturn V Capital Management first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Saturn V Capital Management's Monopar Therapeutics position peaked at $21.3M in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.